Skip to main navigation Skip to search Skip to main content

Erratum: Phospho-valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles (International Journal of Oncology (2017) 51 (1035-1044) DOI: 10.3892/ijo.2017.4103)

  • George Mattheolabakis
  • , Ruixue Wang
  • , Basil Rigas
  • , Gerardo G. Mackenzie

Research output: Contribution to journalComment/debate

Abstract

Subsequently to the publication of the aobve article, the authors have realized that they overlooked including a 'Competing Interests' section. This should have been included in the paper as follows: 'GM, RW and GG M declare they have no competing interests. BR has an equity position in Medicon Pharmaceuticals, Inc., the company that provided the test agent'. The authors regret that this statement was not included in the paper, and apologize for any inconvenience caused.

Original languageEnglish
Pages (from-to)2800
Number of pages1
JournalInternational Journal of Oncology
Volume53
Issue number6
DOIs
StatePublished - 2018

Fingerprint

Dive into the research topics of 'Erratum: Phospho-valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles (International Journal of Oncology (2017) 51 (1035-1044) DOI: 10.3892/ijo.2017.4103)'. Together they form a unique fingerprint.

Cite this